Author: Shapira, Assaf; Benhar, Itai
Title: Toxin-Based Therapeutic Approaches Document date: 2010_10_28
ID: 00cf294x_52
Snippet: To target tumor cells that overexpress the urokinase plasminogen activator system, the furin cleavage site in anthrax PA protein was replaced by sequences that are specifically cleaved by uPA. The modified PA was then combined with FP59, a fusion between the ADP-ribosylation domain of Pseudomonas exotoxin A and amino acids 1-254 of LF (see above). In the presence of pro-uPA and plasminogen, the recombinant complex (PrAg-U2 + FP59) was demonstrate.....
Document: To target tumor cells that overexpress the urokinase plasminogen activator system, the furin cleavage site in anthrax PA protein was replaced by sequences that are specifically cleaved by uPA. The modified PA was then combined with FP59, a fusion between the ADP-ribosylation domain of Pseudomonas exotoxin A and amino acids 1-254 of LF (see above). In the presence of pro-uPA and plasminogen, the recombinant complex (PrAg-U2 + FP59) was demonstrated to be activated selectively on the surface of uPAR-expressing tumor cells from a broad range of human cancers of different origins, and ultimately resulted in specific tumor cell eradication [425, 427] . Subsequent in vivo studies have demonstrated efficient suppression of different murine tumors growth and eradication of established tumors with limited toxicity to normal tissue upon local and systemic administration of the complex [426, 428] . 100% tumor regression and 30% complete histologic remission after systemic administration of tolerated doses of PrAg-U2+FP59 were documented in an in vivo athymic nude mouse model of human non-small cell lung cancer (NSCLC) [429] .
Search related documents:
Co phrase search for related documents- amino acid and cell lung: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- amino acid and cell lung cancer: 1, 2
- amino acid and cleavage site: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76
- amino acid and different origin: 1, 2, 3, 4, 5, 6
- amino acid and efficient suppression: 1
- amino acid and human cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- amino acid and mouse model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- amino acid and murine tumor: 1, 2
- amino acid and normal tissue: 1, 2, 3
- amino acid and PA protein: 1, 2, 3, 4
- amino acid and plasminogen activator: 1, 2
- amino acid and recombinant complex: 1, 2, 3
- amino acid and specifically cleave: 1, 2, 3
- amino acid and systemic administration: 1, 2
- amino acid and tumor cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- amino acid and tumor regression: 1
- amino acid and vivo study: 1, 2, 3, 4, 5, 6, 7, 8, 9
- anthrax PA protein and Pseudomonas ADP ribosylation domain: 1
- anthrax PA protein and tumor cell: 1
Co phrase search for related documents, hyperlinks ordered by date